ArticleWorld journal of gastroenterology2009
Incidence and survival of stomach cancer in a high-risk population of Chile.
Article in World journal of gastroenterology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 79 citations in OpenAlex.
- Cancer in indigenous people in Latin America and the Caribbean: a review.Cancer medicine · 2014Pooled it
- Trial
- Extent of cancer at the time of diagnosis in older adults: a cohort of a Chilean cancer insurance program (2018-2022).Ecancermedicalscience · 2026Article
- Sex disparity, prediagnosis lifestyle factors, and long-term survival of gastric cancer: a multi-center cohort study from China.BMC cancer · 2024Article
- Intersections between innate immune response and gastric cancer development.World journal of gastroenterology · 2023Review
- Arsenic causing gallbladder cancer disease in Bihar.Scientific reports · 2023Article
- Sex Disparity in Patients with Gastric Cancer: A Systematic Review and Meta-Analysis.Journal of oncology · 2022Review
- Estimating the impact of the COVID-19 pandemic on diagnosis and survival of five cancers in Chile from 2020 to 2030: a simulation-based analysis.The Lancet. Oncology · 2021Article
- Perioperative chemotherapy in locally advanced gastric cancer in Chile: from evidence to daily practice.Ecancermedicalscience · 2021Article
- Preparation, characterization, and anticancer efficacy of novel cobalt oxide nanoparticles conjugated with thiosemicarbazide.3 Biotech · 2020Article
- Ethnicity and Health: Experience with an Urban Mapuche Health Program from the Perspective of Key Actors.Journal of racial and ethnic health disparities · 2020Article
- The Anti-Proliferative and Anti-Invasive Effect of Leaf Extracts of Blueberry Plants Treated with Methyl Jasmonate on Human Gastric Cancer In Vitro Is Related to Their Antioxidant Properties.Antioxidants (Basel, Switzerland) · 2020Article
- Assessment of Gastritis and Gastric Cancer Risk in the Chilean Population Using the OLGA System.Pathology oncology research : POR · 2019Article
- Differential Effects of Purinergic Signaling in Gastric Cancer-Derived Cells Through P2Y and P2X Receptors.Frontiers in pharmacology · 2019Article
- MicroRNA-144 functions as a tumor suppressor in gastric cancer by targeting cyclooxygenase-2.Experimental and therapeutic medicine · 2018Article
- Observational
- Potential Diagnostic, Prognostic and Therapeutic Targets of MicroRNAs in Human Gastric Cancer.International journal of molecular sciences · 2016Review
- The current situation for gastric cancer in Chile.Ecancermedicalscience · 2016Review
- A snapshot of cancer in Chile: analytical frameworks for developing a cancer policy.Biological research · 2015Review
- The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance.Virchows Archiv : an international journal of pathology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo study the incidence and survival rate of stomach cancer (SC) and its associated factors in a high risk population in Chile.
methodsThe population-based cancer registry of Valdivia, included in the International Agency for Research on Cancer system, covers 356 396 residents of Valdivia Province, Southern Chile. We studied all SC cases entered in this Registry during 1998-2002 (529 cases). Population data came from the Chilean census (2002). Standardized incidence rates per 100 000 inhabitants (SIR) using the world population, cumulative risk of developing cancer before age 75, and rate ratios by sex, age, ethnicity and social factors were estimated. Relative survival (Ederer II method) and age-standardized estimates (Brenner method) were calculated. Specific survival rates (Kaplan-Meier) were measured at 3 and 5 years and survival curves were analyzed with the Logrank and Breslow tests. Survival was studied in relation to demographics, clinical presentation, laboratory results and medical management of the cases. Those variables significantly associated with survival were later included in a Cox multivariate model.
resultsBetween 1998 and 2002, 529 primary gastric cancers occurred in Valdivia (crude incidence rate 29.2 per 100 000 inhabitants). Most cases were male (69.0%), residents of urban areas (57.5%) and Hispanic (83.2%), with a low education level (84.5% < 8 school years). SC SIR was higher in men than women (40.8 and 14.8 respectively, P < 0.001), risk factors were low education RR 4.4 (95% CI: 2.9-6.8) and 1.6, (95% CI: 1.1-2.1) for women and men respectively and Mapuche ethnicity only significant for women (RR 2.2, 95% CI: 1.2-3.7). Of all cases, 76.4% were histologically confirmed, 11.5% had a death certificate only (DCO), 56.1% were TNM stage IV; 445 cases (84.1%) were eligible for survival analysis, all completed five years follow-up; 42 remained alive, 392 died of SC and 11 died from other causes. Specific 5-year survival, excluding cases with DCO, was 10.6% (95% CI: 7.7-13.5); 5-year relative survival rate was 12.3% (95% CI: 9.1-16.1), men 10.9% (95% CI: 7.4-15.2) and women 16.1% (95% CI: 9.5-24.5). Five-year specific survival was higher for patients aged < 55 years (17.3%), with intestinal type of cancer (14.6%), without metastasis (22.2%), tumor size < 4 cm (60.0%), without lymphatic invasion (77.1%), only involvement of the mucous membrane (100%). Statistically significant independent prognostic factors were: TNM staging, diffuse type, metastasis, supraclavicular adenopathy, palpable tumor, and hepatitis or ascites.
conclusionSocial determinants are the main risk factors for SC, but not for survival. An advanced clinical stage at consultation is the main cause of poor SC survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.